• Upon TFDA issuance of an EUA in Taiwan, an EUA will be issued in Paraguay and Vaxxinity will deliver 1MM doses of its COVID-19 vaccine to Paraguay
• Paraguay suffers one of the worst COVID-19 outbreaks per capita in the world, with more than 400,000 total cases and 11,000 deaths within the population of 7 million
• Vaxxinity�s commitment to Paraguay demonstrates one of its core missions to democratize health worldwide, focusing on countries with the greatest need
• The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.

DALLAS--(BUSINESS WIRE)--Vaxxinity, a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, in close collaboration with UBI-Asia, has announced a purchase order for its COVID-19 vaccine, UB-612, with the Government of Paraguay, contingent upon issuance of an Emergency Use Authorization (EUA) by the Taiwanese Food and Drug Administration (TFDA), which will trigger an EUA in Paraguay. The order was signed on June 16 in Asunci�n by Dr. Julio Borba, Paraguay Minister of Health and Social Welfare, and Jon Harrison, Vaxxinity Chief Strategy Officer. Ambassador Jos� Han, Taiwan�s Ambassador to Paraguay, was also present (pictured).

The UB-612 vaccine is expected to be delivered later this summer, pending issuance of an EUA by the TFDA and subsequent registration by Paraguay�s National Health Surveillance Authority (DINAVISA). As the Ministry of Health and Welfare noted the leadership shown on June 16 by the Government of Paraguay guarantees that Paraguay will be one of the first countries in the world to receive UB-612 once it is issued an EUA.

�Vaxxinity�s foundation is a commitment to democratizing healthcare worldwide,� said Lou Reese, co-founder and executive chairman of Vaxxinity. �Whether by cost, geography, healthcare infrastructure, discrimination, isolation, exclusion, economic or social status, or legacy experience, vaccines to fight the global COVID-19 pandemic have not been distributed equitably to date. Vaxxinity has prioritized its focus on UB-612, while continuing development of the other vaccines in its pipeline, in order to rapidly develop, manufacture, and distribute vaccines to help combat the global COVID-19 pandemic in countries most in need.�

Vaxxinity, in close collaboration with its partner, UBI-Asia, is completing a large Phase 2 clinical trial of UB-612 in Taiwan, with support from Taiwan�s Ministry of Health and Welfare, and will soon begin its Phase 2/3 efficacy trial in India in partnership with Aurobindo. Vaxxinity has also announced a global logistics partnership with Maersk, the world�s largest shipping and integrated logistics provider, that creates a framework for all transportation and supply chain services that will be needed to deliver UB-612 around the world.

The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.

�Our vaccine is designed to stimulate broadly protective immunity protecting the body from future SARS-CoV-2 exposure,� said Mei Mei Hu, co-founder and CEO of Vaxxinity. �In addition, our UB-612 vaccine can be stored at the standard refrigeration range, enabling its distribution using cold-chain solutions readily available in the countries impacted by the COVID-19 pandemic the most. This supports our mission to spearhead the democratization of global healthcare, which will lead to healthier, sustainable, and more productive communities across the world.�

About Vaxxinity, Inc.

Vaxxinity, Inc. is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with partners in the United States, Latin America, Europe, and Asia, the company�s proprietary Multitope technology platform has enabled the innovation of synthetic peptide vaccines designed to treat and prevent infectious diseases, including COVID-19, and chronic diseases, such as Alzheimer�s, Parkinson�s, migraine, and hypercholesterolemia. Unlike vaccines designed to prevent exogenous diseases, Vaxxinity�s chronic disease pipeline is designed to train the body to produce its own antibodies against internal targets of disease. This comes with practical administrative and cost advantages versus monoclonal antibodies, meaning that Vaxxinity may, if approved, offer infrequent IM injection versus frequent IV infusion, and lower costs.

For more information about Vaxxinity, Inc., visit www.vaxxinity.com and follow us on social media @vaxxinity.

Contacts

Diane Murphy, Vaxxinity, Inc.

+1.310.658.8756

[email protected]

David Schull, Russo Partners

+1.212.845.4271

[email protected]